Diabetes Drug Linked to Lower Risk in Elderly

Adults aged 80 and older with chronic kidney disease had lower mortality in a large observational study.

Updated on Nov. 2, 2026 in Diabetes

Diabetes Drug Linked to Lower Risk in Elderly

Live Poll

Would you trust a newer kidney medication for an elderly parent based on real-world data?

A study presented at Kidney Week found that SGLT2 inhibitors were associated with lower mortality in adults aged 80 and older with chronic kidney disease. The analysis covered 23,765 users and nonusers and is relevant to very elderly patients who are often excluded from large clinical trials.

Why it matters

Adults over 80 with kidney disease are historically underrepresented in large randomized trials because of multiple conditions and frailty, so evidence from this age group is limited. This real-world analysis offers population-level evidence that the drug class may be associated with better survival in this group, though it does not establish cause and effect.

This retrospective cohort study matched 23,765 adults aged 80 and older who did or did not use SGLT2 inhibitors, using data from the TriNetX database. After two years, users had an adjusted mortality hazard ratio of 0.734, with the benefit consistent across predefined subgroups, though the observational design cannot prove cause and effect.

The players

Kidney Week

The annual meeting of the American Society of Nephrology, a major global forum for kidney disease research and clinical care.

TriNetX

A global health research network and database that provides real-world electronic health record data used in clinical studies.

The details

SGLT2 inhibitors are a class of medications that act on the kidneys to increase the excretion of glucose in urine, and they are also studied for their effects on heart and kidney protection. Researchers used propensity score matching to compare users and nonusers with similar comorbidities, laboratory values, and frailty-related factors. Because the data came from a large electronic health record database rather than a controlled trial, the study reflects everyday prescribing patterns among very elderly patients.

Timeline

  1. The study was presented at Kidney Week, held October 21 to 25, 2026, in Denver.

  2. Mortality differences were measured after two years of follow-up.

Health Landscape

Large outcome trials of SGLT2 inhibitors established benefits for kidney and heart outcomes in broad adult populations, but people aged 80 and older were poorly represented. This real-world analysis begins to address that gap by examining outcomes in the very elderly, an age group that is growing in number worldwide.

If you are over 80 and have chronic kidney disease, this study suggests SGLT2 inhibitors may be associated with better survival, so it is worth asking your doctor whether this class of medication fits your situation. Because the evidence is observational and presented at a conference, it should be considered alongside your full health picture and not as a reason to change treatment on your own.

The takeaway

Real-world data suggest SGLT2 inhibitors may be linked to better outcomes in the very elderly, a group rarely studied in trials. Anyone in this age group with kidney disease can raise this evidence with their physician during routine care.

Further reading

Explore more on Diabetes, where SGLT2 inhibitors are commonly discussed alongside kidney and heart health.

Live Poll

Would you trust a newer kidney medication for an elderly parent based on real-world data?